G
Guido Kroemer
Researcher at Institut Gustave Roussy
Publications - 1546
Citations - 294816
Guido Kroemer is an academic researcher from Institut Gustave Roussy. The author has contributed to research in topics: Programmed cell death & Apoptosis. The author has an hindex of 236, co-authored 1404 publications receiving 246571 citations. Previous affiliations of Guido Kroemer include Karolinska Institutet & Spanish National Research Council.
Papers
More filters
Journal ArticleDOI
Trial Watch: Toll-like receptor agonists in oncological indications.
Fernando Aranda,Erika Vacchelli,Florine Obrist,Alexander M.M. Eggermont,Jérôme Galon,Catherine Sautès-Fridman,Isabelle Cremer,Jan Henrik ter Meulen,Laurence Zitvogel,Guido Kroemer,Lorenzo Galluzzi +10 more
TL;DR: The number of clinical trials testing the therapeutic potential of both FDA-approved and experimental TLR agonists in cancer patients is stably decreasing, suggesting that drug developers and oncologists are refocusing their interest on alternative immunostimulatory agents.
Journal ArticleDOI
Viral subversion of immunogenic cell death.
Oliver Kepp,Oliver Kepp,Laura Senovilla,Laura Senovilla,Lorenzo Galluzzi,Lorenzo Galluzzi,Theocharis Panaretakis,Antoine Tesniere,Antoine Tesniere,Frédéric Schlemmer,Frédéric Schlemmer,Frank Madeo,Laurence Zitvogel,Laurence Zitvogel,Guido Kroemer,Guido Kroemer +15 more
TL;DR: It is postulate that obligate intracellular pathogens have developed a variety of strategies to subvert CRT exposure, thereby avoiding immunogenic cell death.
Journal ArticleDOI
Mitochondrial liaisons of p53.
Lorenzo Galluzzi,Eugenia Morselli,Eugenia Morselli,Eugenia Morselli,Oliver Kepp,Oliver Kepp,Oliver Kepp,Ilio Vitale,Ilio Vitale,Ilio Vitale,Marcello Pinti,Guido Kroemer +11 more
TL;DR: The tumor suppressor protein p53 is best known for its ability to orchestrate a transcriptional response to stress that can have multiple outcomes, including cell cycle arrest and cell death, but also involves transcription-independent mechanisms.
Journal ArticleDOI
ATM mediates constitutive NF-kappaB activation in high-risk myelodysplastic syndrome and acute myeloid leukemia.
J Grosjean-Raillard,Maximilien Tailler,Maximilien Tailler,Lionel Adès,J-L Perfettini,J-L Perfettini,Claire Fabre,Claire Fabre,Thorsten Braun,S. de Botton,Pierre Fenaux,Guido Kroemer,Guido Kroemer +12 more
TL;DR: Results support the contention that constitutively active ATM accounts for the activation of NF-κB in high-risk MDS and AML, and induced the induction of apoptosis.
Journal ArticleDOI
Immunogenic stress and death of cancer cells: Contribution of antigenicity vs adjuvanticity to immunosurveillance
Norma Bloy,Pauline Garcia,Pauline Garcia,Pauline Garcia,Céline M. Laumont,Jonathan M. Pitt,Jonathan M. Pitt,Antonella Sistigu,Gautier Stoll,Takahiro Yamazaki,Eric Bonneil,Aitziber Buqué,Juliette Humeau,Jan W. Drijfhout,Guillaume Meurice,Steffen Walter,Jens Fritsche,Toni Weinschenk,Hans-Georg Rammensee,Cornelis J. M. Melief,Pierre Thibault,Claude Perreault,Claude Perreault,Jonathan Pol,Laurence Zitvogel,Laura Senovilla,Guido Kroemer +26 more
TL;DR: It is concluded that autophagy and polyploidy increase the immunogenicity of cancer cells mostly by affecting their adjuvanticity rather than their antigenicity.